GRM5 and amyotrophic lateral sclerosis: Selective and more potent mGluR5 antagonists, with more favorable pharmacokinetics, are now available and have been tested in preclinical studies in rodents [70,71,72,73,74,75] and in clinical trials in patients [76,77,78] for pathologies different from ALS, showing a favorable safety profile and good efficacy.